Literature DB >> 28843360

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer.

Patrick Wald1, Xiaokui Mo2, Christian Barney1, Daniel Gunderson1, A Karl Haglund1, Jose Bazan1, John Grecula1, Arnab Chakravarti1, Terence Williams1, David P Carbone3, Meng Xu-Welliver4.   

Abstract

INTRODUCTION: Kilovoltge cone beam computed tomography (kV-CBCT) allows for tumor localization and response assessment during definitive chemoradiotherapy for locally advanced NSCLC. We hypothesize that significant tumor volume loss occurs early during radiotherapy and that the extent of volume loss correlates with clinical outcomes.
METHODS: A total of 52 patients with locally advanced NSCLC treated with definitive chemoradiotherapy were reviewed. kV-CBCT images were used to contour primary gross tumor volumes at four time points during treatment. Patients were dichotomized according to absolute and relative volume changes at each time point. Statistical analyses were performed to evaluate correlations between volume changes and clinical outcomes.
RESULTS: The median gross tumor volumes were 77.1, 48.3, 42.5, and 29.9 cm3 for fractions 1, 11, 21, and final, respectively. Greater relative volume loss between fractions 1 and 21 correlated with improved distant control (hazard ratio [HR] = 0.35, 95% confidence interval [CI]: 0.13-0.94, p = 0.038) and overall survival (HR = 0.40, 95% CI: 0.16-0.98, p = 0.046). Greater relative volume loss between fractions 11 and 21 correlated with improved progression-free survival (HR = 0.39, 95% CI: 0.17-0.88, p = 0.02) and trended toward improved overall survival (HR = 0.43, 95% CI: 0.17-1.06, p = 0.07). On multivariate analysis, greater relative volume loss between fractions 11 and 21 correlated with improved progression-free survival (HR = 0.39, 95% CI: 0.16-0.97, p = 0.041) and overall survival (HR = 0.31, 95% CI: 0.11-0.88, p = 0.027).
CONCLUSIONS: Significant primary tumor volume loss occurs early during radiotherapy for locally advanced NSCLC. Greater relative tumor volume loss during treatment correlates with improved disease control and overall survival. Thus, kV-CBCT has potential to be used as a practical prognostic imaging marker.
Copyright © 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CBCT; Imaging marker; NSCLC; adaptive planning

Mesh:

Year:  2017        PMID: 28843360     DOI: 10.1016/j.jtho.2017.08.010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.

Authors:  Olarn Roengvoraphoj; Chukwuka Eze; Cherylina Wijaya; Maurice Dantes; Julian Taugner; Amanda Tufman; Rudolf Maria Huber; Peter Bartenstein; Claus Belka; Farkhad Manapov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

Review 2.  The Practicality of ICRU and Considerations for Future ICRU Definitions.

Authors:  Annemarie Shepherd; Sara St James; Ramesh Rengan
Journal:  Semin Radiat Oncol       Date:  2018-06       Impact factor: 5.934

3.  Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer.

Authors:  Benedict Osorio; Nikhil Yegya-Raman; Sinae Kim; Charles B Simone; Christina Theodorou Ross; Matthew P Deek; Dakim Gaines; Wei Zou; Liyong Lin; Jyoti Malhotra; Ke Nie; Joseph Aisner; Salma K Jabbour
Journal:  Ann Transl Med       Date:  2019-03

Review 4.  Challenges in the target volume definition of lung cancer radiotherapy.

Authors:  Susan Mercieca; José S A Belderbos; Marcel van Herk
Journal:  Transl Lung Cancer Res       Date:  2021-04

5.  A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors.

Authors:  Misako Nagasaka; Nadine Abdallah; Marcus Crosby; Nithin Thummala; Dhaval Patel; Antoinette J Wozniak; Shirish Gadgeel; Judith Abrams; Ammar Sukari
Journal:  Lung Cancer (Auckl)       Date:  2019-09-12

6.  Tumor regression during radiotherapy for non-small cell lung cancer patients using cone-beam computed tomography images.

Authors:  J E van Timmeren; W van Elmpt; D de Ruysscher; B Reymen; O Hansen; C Brink
Journal:  Strahlenther Onkol       Date:  2019-09-26       Impact factor: 3.621

Review 7.  Liquid Biopsies for Molecular Biology-Based Radiotherapy.

Authors:  Erik S Blomain; Everett J Moding
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

8.  Tumor volume reduction evaluated by cone beam computed tomography during stereotactic body radiotherapy for early stage non-small cell lung cancer.

Authors:  Dakim K Gaines; Nikhil Yegya-Raman; Sinae Kim; Charles B Simone; Christina Theodorou Ross; Matthew P Deek; Sarah Lam; Steven J Feigenberg; Benedict Osorio; Ke Nie; Wei Zou; Malini Patel; Jyoti Malhotra; John Langenfeld; Joseph Aisner; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

9.  Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.

Authors:  Qingjin Qin; Anhui Shi; Ran Zhang; Qiang Wen; Tianye Niu; Jinhu Chen; Qingtao Qiu; Yidong Wan; Xiaorong Sun; Ligang Xing
Journal:  Thorac Cancer       Date:  2020-02-15       Impact factor: 3.500

10.  A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation.

Authors:  Kylie H Kang; Jimmy T Efird; Tarun K Podder; Yuxia Zhang; Afshin Dowlati; Mitchell Machtay; Charulata Jindal; Tithi Biswas
Journal:  Int J Environ Res Public Health       Date:  2021-03-21       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.